Amunix is a leading brand in the field of immuno-oncology, dedicated to conquering cancer and saving lives. With a focus on developing breakthrough therapies that harness the immune system, Amunix utilizes their proprietary PRO-XTEN™ technology platform to discover and create transformative T cell engagers (TCEs) and cytokine therapies for cancer patients. Their goal is to expand the therapeutic index of TCEs and cytokines, which have shown anti-tumor clinical activity but have been limited by on-target, off-tumor toxicity.

Amunix addresses this challenge by utilizing their universal, protease-releasable masking technology (PRO-XTEN) to develop conditionally active TCEs (XPAT® proteins) and cytokines (XPAC™ proteins) that are activated preferentially in tumors compared to healthy tissues. At Amunix, experience and culture matter. They strive to challenge themselves and their colleagues, bringing a critical eye and scientific rigor to everything they do.

With deep experience, diversity of thinking, and scientific rigor, Amunix believes they can make a real difference for cancer patients